Clinical Trial Update: A Study to Learn More About Tukysa Once it is Out in the Korean Market

View source ↗

Summary

Pfizer is planning a clinical trial to study tucatinib (Tukysa) in HER2-positive locally advanced unresectable and metastatic breast cancer in Korea. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tukysa (tucatinib)

Snippet

Sponsor: Pfizer | Conditions: HER2-positive Locally Advanced Unresectable, Metastatic Breast Cancer | Status: NOT_YET_RECRUITING